| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/24/2004 | US6780414 Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cada, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections |
| 08/24/2004 | US6780413 Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders |
| 08/24/2004 | US6780407 Recombinant attenuated avipox virus containing exogenous dna in nonessential region, that expresses exogenous dna encoding carcinoembryonic antigen and exogenous dna encoding b7 protein |
| 08/24/2004 | US6780405 Having first origin of replication conferring low copy number, conferring vector replication using dna polymerase iii, second origin of replication operably linked to first promoter and repressed by chromosome-encoded repressor, as is foreign gene |
| 08/24/2004 | CA2116355C Infectious bovine rhinotracheitis virus mutants and vaccines |
| 08/19/2004 | WO2004070025A2 Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders |
| 08/19/2004 | WO2004070012A2 Cell-killing molecules and methods of use thereof |
| 08/19/2004 | WO2004069876A2 Trimeric polypeptide construct to induce an enduring t cell response |
| 08/19/2004 | WO2004069874A1 Monoclonal antibodies against the ring surface protein 2 (rsp-2) antigen of plasmodium falciparum |
| 08/19/2004 | WO2004069864A1 Polypeptides f' of the hepatitis c virus, epitopes, and the diagnostic and therapeutic applications thereof |
| 08/19/2004 | WO2004069863A2 Constrained hiv v3 loop peptides as immunogens and receptor antagonists |
| 08/19/2004 | WO2004069860A2 Isg15-conjugated proteins |
| 08/19/2004 | WO2004069274A2 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 08/19/2004 | WO2004069272A2 Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
| 08/19/2004 | WO2004069208A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | WO2004069207A2 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | WO2004069206A2 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | WO2004069205A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | WO2004069204A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | WO2004069184A2 Methods for treating, preventing and detecting helicobacter infection |
| 08/19/2004 | WO2004069183A2 Immune regulation based on the targeting of early activation molecules |
| 08/19/2004 | WO2004069182A2 Active immunization to generate antibodies to soluble a-beta |
| 08/19/2004 | WO2004069181A2 Composition for the treatment of intraocular pressure |
| 08/19/2004 | WO2004069176A2 Polymer conjugates of mutated neublastin |
| 08/19/2004 | WO2004069173A2 Methods for modulating an inflammatory response |
| 08/19/2004 | WO2004069166A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 08/19/2004 | WO2004069159A2 Vitamin receptor binding drug delivery conjugates |
| 08/19/2004 | WO2004069142A2 Anti-candida agents for the treatment of prion diseases |
| 08/19/2004 | WO2004052920A9 Conversion of apoptotic proteins |
| 08/19/2004 | WO2004050829A3 Recombinant double-stranded rna phage, and use of the same |
| 08/19/2004 | WO2004044155A8 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| 08/19/2004 | WO2004031222A3 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus |
| 08/19/2004 | WO2004026120A3 Methods for diagnosing and treating tumors and suppressing cd promoters |
| 08/19/2004 | WO2004024076A9 Novel compositions and methods for the treatment of immune related diseases |
| 08/19/2004 | WO2004020452A3 Method for refolding neisserial nspa protein |
| 08/19/2004 | WO2004019912A3 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 08/19/2004 | WO2004017909A3 Methods of reducing ischemic injury |
| 08/19/2004 | WO2004005480A3 Plastid genetic engineering via somatic embryogenesis |
| 08/19/2004 | WO2003095663A3 Modified t lymphocytes and uses therefor |
| 08/19/2004 | WO2003089607A3 Cell wall mannoproteins and active epitopes from candida albicans and antibodies recognizing them |
| 08/19/2004 | WO2003077834A3 Central airway administration for systemic delivery of therapeutics |
| 08/19/2004 | WO2003072720A3 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 08/19/2004 | WO2003066880A3 Method for accessing microbial diversity |
| 08/19/2004 | WO2003053364A3 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 08/19/2004 | WO2003049117A3 Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| 08/19/2004 | WO2003038072A8 Generation and use of new types of dendritic cells |
| 08/19/2004 | US20040162418 Nucleic acids encoding Sarcocystis neurona antigen and uses thereof |
| 08/19/2004 | US20040162262 Immunomodulatory oligonucleotides |
| 08/19/2004 | US20040162258 Immunomodulatory oligonucleotides |
| 08/19/2004 | US20040161843 Administering a peptide fragments from proteins that function as T-cell epitopes of human cytomegalovirus(HCMV) in human are capable of directing human cytotoxic T lymphocytes (CTL) to recognize and lyse human cells to infection with HCMV |
| 08/19/2004 | US20040161840 Bax-Responsive genes for drug target identification in yeast and fungi |
| 08/19/2004 | US20040161825 Sperm specific proteins |
| 08/19/2004 | US20040161824 expressed on the surface of sperm; can be used in contraceptive vaccine formulations; for drug screening; genetic engineering |
| 08/19/2004 | US20040161816 Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| 08/19/2004 | US20040161806 Cells having transferred proteins, and methods of use thereof |
| 08/19/2004 | US20040161745 Nucleotide sequences coding glucuronidase for identifying modulators for treatment of inflammation; wound healing agents and tissue repair |
| 08/19/2004 | US20040161475 Anticancer, antitumor agents; ssynergistic mixtures with retinoic acid; olid tumors |
| 08/19/2004 | US20040161470 Encapsulation of active material in polyphosphazenes |
| 08/19/2004 | US20040161433 Method for in vitro culture of lymphocytes and composition for use in immune therapy |
| 08/19/2004 | US20040161432 Subunit vaccines and processes for the production thereof |
| 08/19/2004 | US20040161429 Safe and effective vascular targeting, angiogenesis inhibiting and tumor treatment using single component antibody based therapeutics that bind to anionic phospholipids |
| 08/19/2004 | US20040161426 Use of IL-6 antagonists in combination with steroids to enhance apoptosis |
| 08/19/2004 | US20040161425 Chemokine receptor antagonists as therapeutic agents |
| 08/19/2004 | US20040161420 Designed for bacterial live vector vaccines; does not rely on antibiotic resistance; stability |
| 08/19/2004 | US20040161417 Inhibiting expression of invariant chain protein (li) in antigen presenting cells |
| 08/19/2004 | US20040161413 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 08/19/2004 | US20040161410 Involving nucleotide sequence 15 or 19; efficient, well tolerated |
| 08/19/2004 | US20040161409 Induction of immune response to antigens expressed by recombinant adeno-associated virus |
| 08/19/2004 | CA2515302A1 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 08/19/2004 | CA2515125A1 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515123A1 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515122A1 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515112A1 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515107A1 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 08/19/2004 | CA2515100A1 Trimeric polypeptide construct to induce an enduring t cell response |
| 08/19/2004 | CA2514841A1 Cell-killing molecules and methods of use thereof |
| 08/19/2004 | CA2514641A1 Methods for modulating an inflammatory response |
| 08/19/2004 | CA2514576A1 Methods for treating, preventing and detecting helicobacter infection |
| 08/19/2004 | CA2514563A1 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 08/19/2004 | CA2514510A1 Polymer conjugates of mutated neublastin |
| 08/19/2004 | CA2513905A1 Immune regulation based on the targeting of early activation molecules |
| 08/19/2004 | CA2513722A1 Active immunization to generate antibodies to soluble a-beta |
| 08/19/2004 | CA2512867A1 Vitamin receptor binding drug delivery conjugates |
| 08/18/2004 | EP1447451A1 MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND-BETA2m AND UTILIZATION THEREOF |
| 08/18/2004 | EP1447414A2 Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| 08/18/2004 | EP1447411A1 Novel protein, its dna and use thereof |
| 08/18/2004 | EP1447099A2 Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same |
| 08/18/2004 | EP1447093A1 Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 08/18/2004 | EP1447092A1 Methods of inducing antigen-specific t cells |
| 08/18/2004 | EP1447091A1 Novel method of inducing antigen-specific t cells |
| 08/18/2004 | EP1447080A1 Method for producing virosome-like particles |
| 08/18/2004 | EP1446501A2 Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| 08/18/2004 | EP1446425A2 Treatment of micro-organism infection |
| 08/18/2004 | EP1446424A2 Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| 08/18/2004 | EP1446422A2 Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same |
| 08/18/2004 | EP1446420A2 Virulence proteins of the genus yersinia and uses thereof |
| 08/18/2004 | EP1446416A1 Tumor specific monoclonal antibodies |
| 08/18/2004 | EP1446159A2 Immunotherapy for reversing immune suppression |
| 08/18/2004 | EP1446156A2 Method to obtain protection against bystander allergen |
| 08/18/2004 | EP1446153A1 Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors |